Novozymes' bioenergy suffers hard impact from reduced US consumption
The enzyme firm is confident enough to reinstate a full-year guidance but lost DKK 252 million in Q2 compared to last year. The bioenergy division is particularly hard hit.
BY RITZAU FINANS
Novozymes' sales of enzymes for use in bioenergy declined organically by a massive 37 percent in the second quarter of 2020, with the division's top line coming to DKK 439 million (EUR 58.8 million), according to the company's second-quarter 2020 financial report, published Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novozymes finishes difficult 2019 burdened by bioenergy
For subscribers
.jpg&w=384&q=75){kind=logo}
